Please add "communications@pancan.org" to your Email Address Book. Learn how.
Recalcitrant Cancer Research Act Signed into Law!

» Historic milestone reached in the fight against pancreatic cancer.

Finding the Right Clinical Trial
Clinical trials bring about treatment advances. Call PALS today for a personalized clinical trials search and learn about your options.
Clinical Trials
Process Explained

Hear directly from a clinical trials patient about participating in a trial and learn the truth about some common misperceptions.
Resolve to Get Involved
Start the new year off right – become a volunteer leader in your community. Learn more.
Research
Find out how the rationale for most clinical trials begins in the laboratory.
Kick Off the New
Year in Purple

Show your support in 2013 by sporting one of our eye-catching wind jackets. Shop now for this item and other apparel.
Historic Cancer
Bill Becomes Law!

On January 2, President Obama signed into law the defense bill, which included the Recalcitrant Cancer Research Act!
Keep the
Memory Alive

Create an honorary tribute page for your loved one and help everyone affected by this devastating disease.
Sponsor a Stride
Engage your employees, customers and partners in our powerful 2013 community events as a sponsor. And a huge thank you to our 2012 Presenting Sponsors.

A message from the President and CEO

In recognition of January as National Pancreatic Cancer Clinical Trials Awareness Month, our guest columnist this month is Jordan Berlin, MD, who serves as Associate Professor and Co-Director of GI Oncology and Phase I Program at the Vanderbilt University Medical Center in Nashville, Tennessee. Dr. Berlin has also been a member of the Pancreatic Cancer Action Network Medical Advisory Board since 2006 and is currently serving as its Chair. He has a strong interest in the design of effective clinical trials, and is a dedicated advocate for patient participation in them.

With warm regards,

Julie Fleshman, JD, MBA
President and CEO
Pancreatic Cancer Action Network




Dear Pancreatic Cancer Action Network Friends:

A new year is upon us, and I am encouraged that the clinical environment for pancreatic cancer continues to make headway.

The first example involves Celgene Corporation’s recent announcement that in their recently completed clinical trial, their drug Abraxane, when combined with gemcitabine, showed a statistical improvement in overall survival in patients with metastatic pancreatic cancer. The supporting data is expected to be released next week and should provide illumination to this announcement, perhaps changing the way that we approach treatment for pancreatic cancer patients.

CLICK HERE TO READ DR. BERLIN'S ENTIRE LETTER

 

For information about including the Pancreatic Cancer Action Network in your estate planning,
click here.

 

Privacy Policy              Manage your subscriptions               Unsubscribe